The Neurodegenerative Disease Market size is estimated to reach $49,218 million by 2027. Furthermore, it is poised to grow at a CAGR of 3.9% over the forecast period of 2022-2027. Neurodegenerative diseases are a set of brain disorders that cause the structure and function of neurons in the central nervous system (CNS) and peripheral nervous system (PNS) to deteriorate over time (PNS). Several drugs are currently available to help people lessen physical or mental symptoms and improve their quality of life. Furthermore, researchers are concentrating their efforts on developing molecular diagnostics, particularly biomarkers and imaging spectroscopy, in order to detect and diagnose neurodegenerative illnesses at an early stage and halt their progression. The impact of COVID-19 on the neurodegenerative disease market is projected to be significant, as the pandemic has disrupted clinical trial, research and development, and pipeline product workflows, resulting in relatively modest growth during the pandemic despite a solid late-stage product pipeline. Despite the pandemic the market is forecasted to gradually recover and grow in the years of forecast. The companies with higher funding and revenue are investing more into R&D with development of unique neurodegenerative disease drugs for the various neurodegenerative indications while expanding to new geographic locations through its sales channel expansion. Recently, companies are focusing on making continuous investment across the business to in order to build and maintain the pipeline of new drugs for therapeutics. Companies are also predicted to acquire, grow the foreign market revenue and continue to get timely regulatory approvals. Rising prevalence of Alzheimer disease, increasing public awareness, and a strong product pipeline for neurodegenerative disease treatment are some of the factors driving the drug Industry forward in the projected period of 2022-2027.
Report Coverage
The report: “Neurodegenerative Disease Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Neurodegenerative Disease Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021. The growing geriatric population in the US is increasing the prevalence of neurodegenerative diseases as age is the best known risk factor for such diseases. The geriatric population was estimated to be around 65 million in 2020. This is projected to increase by 18 million between 2020 and 2030 and it is estimated that approximately 1 in every 5 Americans will be 65 or more by 2030..
- The surge in neurodegenerative diseases in the US owing to the rising geriatric population is increasing the demand for effective neurodegenerative disease therapies for treating the disease and suppressing symptoms. In addition, it has also resulted in an increase in public R&D expenditure towards drug research, which will further contribute to the market growth. For instance, the Federal Alzheimer's and Dementia Research Funding increased from $2.8 billion in 2019 to $3.2 in 2021.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Neurodegenerative Disease Market Report.
Neurodegenerative Disease Market Segmentation Analysis- By Drug Class
The neurodegenerative disease market based on drug class can be further segmented into N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Acetylcholinesterase (AChE) Inhibitors, Dopamine Agonists and Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor. Immunomodulators held a dominant market share in the year 2021. Immunomodulators provides very effective therapy options for a variety of autoimmune and neurodegenerative illnesses. Furthermore, the growing presence of important companies is likely to raise patient and physician awareness of the benefits of immunomodulators. As they strive to obtain a competitive advantage in the market, they are developing novel immunomodulators to treat a variety of chronic conditions.
However, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors is estimated to be the fastest-growing, with a CAGR of 13.3% over the forecast period of 2022-2027. It is owing to increase in number of patients with bipolar diseases, schizophrenia, and Huntington’s disease and other neuropsychiatric disorders undergoing long-term medical treatments with antipsychotic medication. Furthermore, throughout the projected period, investigational research for the discovery of novel therapies using VMAT2 inhibitors to treat Huntington disease are expected to drive demand.
Neurodegenerative Disease Market Segmentation Analysis- By Indications
The neurodegenerative disease market based on indications can be further segmented into Parkinson’s Disease, Huntington Disease, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Spinal Muscular Atrophy (SMA) and Others. Multiple Sclerosis held a dominant market share in the year 2021. Recently, more than 4,00,000 people in U.S. are suffering from multiple sclerosis which is rising the adoption of various types of drug class, so the demand for neurodegenerative drugs is expanding. Apart from this, the breakout of the COVID-19 pandemic has had a significant impact on the growth of the multiple sclerosis medications, as it has disrupted the supply chains of numerous important participants in the industry. For example, Biogen announced that sales of one of its important medications, TECFIDERA, which is used to treat multiple sclerosis, fell by 13% in 2020 compared to the previous year such factors are predicted to have a minor impact on market expansion.
However, Huntington Disease is estimated to be the fastest-growing, with a CAGR of 13.2% over the forecast period of 2022-2027. It is owing to various factors such as greater adoption of novel drugs, expanded R&D activity, an increase in the target population, and supportive regulatory measures are all driving the Huntington's Disease incidence. Reportedly, more than 20 drugs are in various phases of clinical trials for the treatment of Huntington's disease.
Neurodegenerative Disease Market Segmentation Analysis- By Geography
The neurodegenerative disease market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 3.1% in the year 2021 as compared to the other counterparts. It is owing to increasing prevalence of neurodegenerative diseases such as Alzheimer diseases, Huntington disease etc. According to the Centers for Disease Control (CDC), Alzheimer's disease is the 6th leading cause of death among US adults. In 2020, it is estimated that more than 5.8 million Americans aged 65 years or older are suffering from Alzheimer’s disease. This is projected to reach 7.7 million by 2030. Meanwhile, according to the Parkinson’s Foundation Prevalence Project, the prevalence of Parkinson’s in the US is predicted to rise from 930,000 in 2020 to 1.2 million by 2030.
Neurodegenerative Disease Market Drivers
Rising prevalence of Alzheimer disease have readily aided the market growth
Alzheimer's disease is a degenerative neurological disease and the most common form of dementia, characterised by memory loss, loss of thinking skills, and difficulties with problem-solving and language. Alzheimer's disease symptoms appear gradually over many years and eventually grow more severe. According to the World Health Organization (WHO), in 2021 over 50 million individuals suffer from dementia, a frequent form of Alzheimer's disease, with 10 million new cases diagnosed each year. The increased prevalence of these disorders also drives the development of various medications. Besides, the market is growing as people become more aware of the drug therapies for Alzheimer's disease around the world. Furthermore, rising awareness of the different novel treatment alternatives, is also helping to fuel the rise of Alzheimer's Drugs.
Availability of robust pipeline of drugs for neurodegenerative disease treatment is driving the market growth
Availability of robust pipeline of drugs for neurodegenerative disorders is forecasted to drive growth of the global Neurodegenerative Disease Market. Recently, in 2021, GlaxoSmithKline Plc in collaboration with Alector Inc. to develop antibody-based treatments for Parkinson's, Alzheimer's and other similar diseases. This collaboration deals worth up to $2.2 billion which efforts to build a robust pipeline of drugs.
Neurodegenerative Disease Market Challenges
High cost of treatment are some of the factors impeding the market growth
The extremely high cost is anticipated to hamper market growth as it limits the access of quality treatment to the middle and low-income population countries. For instance, in U.S. the average annual medical cost for the treatment of Multiple Sclerosis (MS) can reach more than $70,000. This is highly expensive as the country’s median household income in 2020 was only $67,521.
Neurodegenerative Disease Market Competitive Landscape
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Neurodegenerative Disease Market. The top 10- Neurodegenerative Disease Market companies are-
- Biogen Inc.,
- F. Hoffman La Roche Ltd.,
- Merck KGaA,
- Novartis AG,
- Sanofi,
- Teva Pharmaceuticals Industries Ltd.,
- Orion Corporation,
- H. Lundbeck A/S.,
- Sun Pharmaceutical Industries Ltd.,
- UCB S.A.
Recent Developments
- In May 2021, Biogen Inc. and Envisagenics announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases. As part of the collaboration, Biogen will leverage Envisagenics’ proprietary artificial intelligence (AI)-driven RNA splicing platform, SpliceCore®, to define and understand the regulation of different RNA isoforms in CNS cell types.
- In August 2020, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. This is predicted to drive the SMA indication segment.
- In February 2020, Novartis announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.
